News We’re Watching: Trial Lab Warning Letters, Novartis Adds US Plants, Abbott Launches OTC Lingo Glucose Monitor

 
• By Natasha Barrow, Elizabeth Orr, and Brian Bossetta

This week, two device testing labs in China landed FDA warning letters; refunds for 1Health.io clients; FDA AR/VR product list expands. 

"News We're Watching" Feature Image
• Source: Medtech Insight

More from Approvals

More from Policy & Regulation